Emergent Biosolutions (NYSE:EBS) Shares Up 10.4% – Still a Buy?

Emergent Biosolutions Inc. (NYSE:EBS)’s share price was up 10.4% during trading on Friday . The company traded as high as $9.95 and last traded at $10.0260. Approximately 575,262 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 1,209,743 shares. The stock had previously closed at $9.08.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on EBS. Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Finally, Zacks Research raised Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $15.00.

Emergent Biosolutions Stock Up 11.7%

The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00. The company has a market capitalization of $532.55 million, a PE ratio of 7.77 and a beta of 2.06. The business’s 50 day simple moving average is $9.51 and its 200 day simple moving average is $7.90.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. The firm had revenue of $222.50 million for the quarter. Emergent Biosolutions had a return on equity of 21.43% and a net margin of 9.62%. Emergent Biosolutions has set its FY 2023 guidance at EPS. As a group, analysts anticipate that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Coleen Glessner sold 30,608 shares of the company’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the transaction, the executive vice president owned 144,319 shares of the company’s stock, valued at $1,443,190. This represents a 17.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Institutional Trading of Emergent Biosolutions

Hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC increased its position in shares of Emergent Biosolutions by 313.5% during the first quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock valued at $4,048,000 after acquiring an additional 631,794 shares during the last quarter. Wolverine Asset Management LLC boosted its position in shares of Emergent Biosolutions by 28.3% during the 2nd quarter. Wolverine Asset Management LLC now owns 174,933 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 38,600 shares during the period. Prescott Group Capital Management L.L.C. increased its holdings in Emergent Biosolutions by 198.9% in the 1st quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock valued at $3,050,000 after purchasing an additional 417,671 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Emergent Biosolutions by 12.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after purchasing an additional 121,583 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in Emergent Biosolutions by 22.4% during the first quarter. New York State Common Retirement Fund now owns 375,034 shares of the biopharmaceutical company’s stock worth $1,823,000 after purchasing an additional 68,748 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.